ampelopsin has been researched along with Metabolic Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, P; Ji, G; Wang, J; Wang, Y; Wu, T; Xiang, H | 1 |
| Huang, S; Jin, R; Li, X; Tan, L; Tong, H; Zhang, X | 1 |
2 review(s) available for ampelopsin and Metabolic Diseases
| Article | Year |
|---|---|
Recent update on application of dihydromyricetin in metabolic related diseases.
Topics: AMP-Activated Protein Kinases; Anti-Inflammatory Agents; Antioxidants; Cell Death; Flavonols; Glucose; Humans; Lipid Metabolism; Liver Diseases; Metabolic Diseases; MicroRNAs; Neoplasms; Oxidative Stress; Peroxisome Proliferator-Activated Receptors; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2022 |
Multitarget and promising role of dihydromyricetin in the treatment of metabolic diseases.
Topics: Animals; Atherosclerosis; Diabetes Mellitus; Flavonols; Gene Expression Regulation; Humans; Hypoglycemic Agents; Metabolic Diseases; Non-alcoholic Fatty Liver Disease; Osteoporosis; Signal Transduction | 2020 |